Relacorilant is a clinical-stage drug being developed for the treatment of Cushing’s syndrome is a rare endocrine disorder caused by excessive levels of cortisol in the body. The most common cause of Cushing’s syndrome is often exogenous due to chronic glucocorticoid therapy. But Cushing’s syndrome can also arise from endogenous factors, especially adrenal or pituitary tumors, leading to serious health issues such as increased hypertension and risk of myocardial infarction or stroke and chronic complications like obesity, diabetes, osteoporosis. If untreated, it has high potential causing life-threatening conditions. This disease affects approximately 10-15 per million people annually, with an estimated 3,000-5,000 new cases in the U.S. each year (1).. It is being developed by Corcept Therapeutics Incorporated. The FDA Prescription Drug User Fee Act (PDUFA) date is December 29, 2025. Premium analysis including detailed clinical trial status, revenue predictions, and comprehensive company insights are available for members.